journal article·2025-12-10

Bacterial Membrane Coating Potentiates Lipid Nanoparticles for mRNA Delivery

Rui Wang, Lin Bao, Yiyan Yu, Runhe Zhang, Zhongyuan Guo, Luke J. Kubiatowicz, Nishta Krishnan, Ilkoo Noh, Edward Wang, Ronnie H. Fang, Weiwei Gao, Liangfang Zhang

Nano Letters· Volume 25· Issue 49
Publisher page

Abstract

Bacterial outer membrane vesicles (OMVs) possess intrinsic immunostimulatory properties by carrying native antigens and pathogen-associated molecular patterns (PAMPs). Lipid nanoparticles (LNPs) have become the leading platform for messenger ribonucleic acid (mRNA) delivery, underpinning the clinical success of mRNA vaccines. Here, we developed a hybrid nanoparticle formulation, OMV-coated LNPs (OMV-LNPs), that combines the high delivery efficiency of LNPs with the immunogenicity of the OMVs to enhance gene delivery. Using Escherichia coli -derived OMVs and dengue virus (DENV) E80 protein as a model antigen, we generated OMV-LNPs encapsulating DENV mRNA (OMV-LNP mRNA ). These nanoparticles demonstrated improved uptake by lymph-node-resident immune cells and enhanced cytosolic mRNA delivery, resulting in robust dendritic cell maturation and proinflammatory cytokine production in vitro . In AG129 mice, the OMV-LNP mRNA elicited significantly higher titers of DENV-neutralizing antibodies compared to conventional LNPs. Collectively, these results establish OMV-LNPs as a versatile and potent platform for effective mRNA vaccine delivery.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Bacterial Infections and Vaccines · Cancer Research and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Aiiso Yufeng Li Family Department of Chemical and Nano Engineering, Shu and K. C. Chien and Peter Farrell Collaboratory

University of California─San Diego

Funding

Defense Threat Reduction Agency

References (31)

Show source-provided references
1. 10.1073/pnas.110663410810.1073/pnas.1106634108 ↗
2. 10.1002/adma.20170675910.1002/adma.201706759 ↗
3. 10.1021/nl504798g10.1021/nl504798g ↗
4. 10.1002/anbr.20220013010.1002/anbr.202200130 ↗
5. 10.1002/pmic.20080027310.1002/pmic.200800273 ↗
6. 10.3390/pharmaceutics1302013110.3390/pharmaceutics13020131 ↗
7. 10.1101/gad.129990510.1101/gad.1299905 ↗
8. 10.1038/nri383710.1038/nri3837 ↗
9. 10.1038/s41467-021-22308-810.1038/s41467-021-22308-8 ↗
10. 10.1016/j.biomaterials.2023.12206510.1016/j.biomaterials.2023.122065 ↗
11. 10.1038/s41573-021-00283-510.1038/s41573-021-00283-5 ↗
12. 10.1038/nrd427810.1038/nrd4278 ↗
13. 10.1038/nrd.2016.28010.1038/nrd.2016.280 ↗
14. 10.1038/s41563-024-02116-310.1038/s41563-024-02116-3 ↗
15. 10.1038/s41563-025-02240-810.1038/s41563-025-02240-8 ↗
16. 10.1038/s41565-019-0591-y10.1038/s41565-019-0591-y ↗
17. 10.1016/S0140-6736(23)02444-310.1016/S0140-6736(23)02444-3 ↗
18. 10.1038/s41587-022-01491-z10.1038/s41587-022-01491-z ↗
19. 10.1038/s41573-024-01042-y10.1038/s41573-024-01042-y ↗
20. 10.1016/j.lanepe.2021.10020810.1016/j.lanepe.2021.100208 ↗
21. 10.1172/JCI16795510.1172/JCI167955 ↗
22. 10.1002/adma.20210998410.1002/adma.202109984 ↗
23. 10.1002/advs.20230242310.1002/advs.202302423 ↗
24. 10.1038/s41590-022-01168-410.1038/s41590-022-01168-4 ↗
25. 10.1038/s41541-023-00760-510.1038/s41541-023-00760-5 ↗
26. 10.1080/15476286.2024.233312310.1080/15476286.2024.2333123 ↗
27. 10.3389/fimmu.2025.152096810.3389/fimmu.2025.1520968 ↗
28. 10.1016/j.vaccine.2017.09.06310.1016/j.vaccine.2017.09.063 ↗
29. 10.1016/j.omtm.2020.07.01310.1016/j.omtm.2020.07.013 ↗
30. 10.1038/s41551-025-01343-610.1038/s41551-025-01343-6 ↗
31. 10.1128/JVI.02482-2010.1128/JVI.02482-20 ↗